 SHELTON, CT ACCESSWIRE May 4, 2020 NanoViricides, Inc. NYSE American:NNVC the Company a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that it has signed a Confidential Disclosure Agreement CDA with a leading pharmaceutical company in the Asian region to explore collaborating on the Companys COVID-19 program. NanoViricides previously disclosed that it has already identified certain drug candidates that are active against multiple coronaviruses in cell culture studies. The Company intends to perform testing against SARS-CoV-2 the virus that causes COVID-19 disease and is in advanced discussions with at least two sites that have such capability. 